Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer

The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy and optimal dosage of trastuzumab deruxtecan (T-DXd) in managing the human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment.The study sought to assess the cost-effectiveness of T-DXd in b

read more

Clinician perspectives and recommendations regarding design of clinical prediction models for deteriorating patients in acute care

Abstract Background Successful deployment of clinical prediction models for clinical deterioration relates not only to predictive performance but to integration into the decision making process.Models may demonstrate good discrimination and calibration, but fail to match the needs of practising acute care clinicians who receive, interpret, and act

read more